Research Article | Open Access
Fan Wang, Pei Li, Fengsen Li, "Nomogram for Predicting the Relationship between the Extent of Visceral Pleural Invasion and Survival in Non-Small-Cell Lung Cancer", Canadian Respiratory Journal, vol. 2021, Article ID 8816860, 9 pages, 2021. https://doi.org/10.1155/2021/8816860
Nomogram for Predicting the Relationship between the Extent of Visceral Pleural Invasion and Survival in Non-Small-Cell Lung Cancer
Objective. Although visceral pleural invasion (VPI) has already been incorporated into the TNM staging system, few studies have been conducted to evaluate the prognostic value of the extent of VPI for the survival of non-small-cell lung cancer (NSCLC) patients. Thus, we utilized the Surveillance, Epidemiology, and End Results (SEER) database to assess the correlation between the extent of VPI and survival in NSCLC. Methods. We identified and incorporated the extent of VPI to build a prognostic nomogram in this study. Patients in the SEER database diagnosed with NSCLC (n = 87,045) from 2010 to 2015 were further analyzed and randomly assigned into either the training group (n = 60,933) or validation group (n = 26,112). Clinical variables were calculated by means of multivariate Cox regressions and incorporated into the predictive model. Subsequently, the accuracy and discrimination of nomogram were further assessed through the concordance index (C-index), calibration curves, and Kaplan–Meier curves. Results. Multivariate analysis demonstrated that the extent of visceral pleural invasion was an independent and unfavorable prognostic factor. The C-indexes of the training and validation groups were 0.772 (95% CI: 0.770–0.774) and 0.769 (95% CI: 0.765–0.773), respectively, which revealed that the nomogram had sufficient credibility and stable predictive accuracy. The calibration curve displayed consistency between the actual and predictive values in both training and validation groups. Conclusion. The prognostic nomogram with the extent of VPI could offer an accurate risk evaluation for patients with NSCLC. Independent external validation of this research should be conducted in the future.
Lung cancer is a group of clinically and histologically heterogeneous diseases and is the leading cause of cancer-related mortality worldwide . Lung cancer is diagnosed in approximately 2.1 million people annually worldwide, with about 1.8 million people die of this disease . Among patients, approximately 85% of patients were classified as having non-small-cell lung cancer (NSCLC). The 5-year survival rate for NSCLC patients ranges from 4% to 17% due to stage and geographic differences .
Visceral pleural invasion (VPI) has been identified as a poor prognostic factor in NSCLC and was first adopted as a T descriptor in the 5th edition of the TNM classification criteria in the 1970s . According to the International Association for the Study of Lung Cancer (IASLC) standard classification, PL0 has been defined as there is no evidence of visceral pleural invasion surpassing the elastic layer; PL1 has been identified as the invasion surpassing the elastic layer; PL2 represents the invasion to the pleural surface; and PL3 indicates the invasion to the parietal pleural, thoracic wall, or both [5, 6]. In the recently updated 7th and 8th editions of the American Joint Committee on Cancer (AJCC) staging system, VPI regarded as a non-size-based T2 factor, which was previously determined to be T1 stage, is now considered to be T2a stage [6, 7]. Although the prognostic value of VPI has been widely recognized, some studies have argued that the extent of VPI has a limited impact on the survival of lung cancer patients [8, 9]. It remains controversial whether the extent of VPI affects the survival of NSCLC patients.
We must assess clinicopathological prognosis factors, including histological classification, tumor differentiation, tumor size, and so on, to estimate the accurate prognosis and deliver personalized treatment strategies for NSCLC patients. How to determine the subdivision level of VPI has some limitations in clinical application, which is usually due to being diagnosed by imaging features and clinical judgment rather than pathological diagnosis. VPI in NSCLC patients is usually determined by the tumor site, radiographic findings, and other clinical characteristics; therefore, patients have variable clinical outcomes. Moreover, although VPI has been incorporated into the existing TNM staging system of AJCC, the relationship between the subdivision of VPI and prognosis in the NSCLC patients continues to have a great deal of ambiguity. Based on these reasons, we are proposing the use of additional prognostic models to evaluate the survival outcomes of these patients.
Nomography, as a prognostic tool, can integrate predictive factors to establish a statistical model and has been extensively applied to predict the survival outcomes of various cancer patients [10, 11]. So far, no relevant nomogram involving the subdivisions of VPI has been established to predict prognosis in NSCLC patients. Therefore, we aimed to establish a nomogram that can visualize the survival prediction results of NSCLC patients with different extents of VPI by analyzing data from the Surveillance, Epidemiology, and End Results (SEER) database.
2.1. Data Abstraction
The SEER database, which has primary sources of population-based cancer statistics in the USA, capturing approximately 97% of cancer incidence and covering about 28% of the USA population in 17 SEER registries, is maintained by the National Cancer Institute (NCI)  (https://seer.cancergov/). We extracted the data of non-small-cell lung cancer patients from the SEER database using the SEERStat program (v 8.2.1). The classification of VPI was based on the proposal of the International Association for the Study of Lung Cancer (IASLC) . According to the SEER data term, CS Site-Specific Factor 2, the subdivision level of VPI confirmed by pathology was introduced in this database in 2010. Therefore, we retrieved only the data of lung cancer patients diagnosed by pathology from 2010 to 2015 and initially obtained a total of 443,960 patients. The included criteria to further screen the patients were as follows: (1) all included subjects needed to be histopathologically confirmed as NSCLC; (2) histological subtypes, including squamous cell carcinoma, adenocarcinoma, large-cell carcinoma, and bronchioalveolar carcinoma, were assigned according to the World Health Organization (WHO) classification system; (3) definite diagnosis of NSCLC was primary and unique; (4) the degree of visceral pleural invasion and survival status was definite; (5) comprehensive clinical information, such as race, sex, age, marital status, T stage, N stage, M stage, tumor grade, survival month, vital status, and the extent of VPI, were recorded. The excluded criteria were as follows: (1) incomplete clinical data involving survival time; T, N, and M stage; and the subdivision level of VPI and (2) histologically confirmed as small-cell lung cancer. The eligible data of NSCLC patients were randomly divided into either the training group (n = 60,933) or the validation group (n = 26,112) at a ratio of 7:3.
2.2. Variable Definition
The study variables were recorded as follows: gender (female and male), race (black, white, and others), T stage (T0, T1, T2, T3, and T4), N stage (N0, N1, N2, and N3), M stage (M0 and M1), tumor grade (well-differentiated, Grade I; moderately differentiated, Grade II; poorly differentiated, Grade III; and undifferentiated, Grade IV), histologic classification (adenocarcinoma, squamous cell carcinoma, large-cell carcinoma, and bronchioalveolar carcinoma), marital status (married (including common law), divorced, single (never married), widowed, and unknown), the extent of VPI (no evidence of visceral pleural invasion based on clinical and/or pathological judgment, PLx; tumor confined within the lung parenchyma or does not fully invade beyond the elastic layer based on histopathological evidence, PL0; tumor penetrates beyond the elastic layer based on histopathological evidence, PL1; tumor penetrates to the surface of the visceral pleura based on histopathological evidence, PL2; and tumor extends to the parietal pleura based on histopathological evidence, PL3). The primary end point was overall survival (OS), which was calculated starting from the date of diagnosis to death by any cause.
We obtained permission to retrieve the SEER research data files with the reference number 16828-Nov2017. The research data used in this study did not involve the subjects or individual identification information. Therefore, this study did not require informed consent and ethical approval.
2.3. Statistical Analysis
We used R software version 3.5.1 to perform statistical analysis and generate graphics (R Foundation for Statistical Computing, Vienna, Austria). The continuous variables were converted to categorical variables and calculated using the Chi-squared test. The survival curve for OS was displayed using the Kaplan–Meier method, and differences were tested using a log-rank test stratified based on the prognostic factors. The Cox proportional hazards multivariate regression was used to analyze further the variables with -values less than or equal to 0.05, which had been calculated using the univariate analysis.
The graphical nomogram was obtained using the logistic regression model from the training group using the R package rms. The maximum points for each variable were set to 100. The discrimination and predictive powers of the nomogram model were evaluated using the concordance index (C-index) . The discrimination ability of the prognosis model gradually increased with the increase in scores, the value of the C-index with 0.5 representing a random chance and 1.0 representing a fully corrected discrimination ability. The calibration plots of the nomogram for 3- and 5-year OS, which used bootstraps of 200 resamples, were constructed to evaluate the consistency between the predictive and actual survivals. A two-tailed -value of less than 0.05 was considered statistically significant.
3.1. Characteristics of Patients
This study initially included a total of 87,045 lung cancer patients from the SEER research database from 2010 to 2015 that subsequently was randomly divided into either the training group (n = 60,933) or the validation group (n = 26,112) at a ratio of 7:3. The selection process is presented in a detailed flow chart (Figure 1), and the demographic characteristics are listed in Table 1. Among these patients, 42,199 (48.5%) were female, and 44,846 (51.5%) were male. The majority of the initially included patients were married elderly patients (>60 years) and had adenocarcinoma and a tumor grade of III.
Note: AC: adenocarcinoma; BAC: bronchioalveolar carcinoma; LCC: large-cell carcinoma; SC: squamous cell carcinoma.
3.2. Prognostic Factors Associated with OS
The variables of the training group including gender, age, race, marital status, histology classification, tumor grade, TNM stage, and the subdivision of the VPI, were incorporated into the univariate analysis. All selected variables with a -value of less than 0.05 using the univariate analysis were determined as risk factors and were subsequently further analyzed using Cox proportional hazards multivariate regression. Ultimately, the analysis results showed that these variables, obtained by the univariate and multivariate analysis, were independent prognostic factors (Table 2).
3.3. Nomogram Construction and Validation
Based on these results, these factors were determined to be independent prognostic factors and then incorporated into the construction of the nomogram predicting 3- and 5-year overall survival (OS) in the training group (Figure 2). This nomogram predictive model revealed that M stage had the biggest impact on prognosis, followed by the extent of VPI, histology type, T stage, tumor grade, N stage, age, gender, pleural, and race. The score of each prognostic factor was identified using the point scale drawn by the intersection of the vertical line from each variable to the point axis. Next, the 3- and 5-year survival probabilities were acquired by adding the score of each prognostic factor. Higher scores among patients correlated with decreased survival. The C-index was 0.772 (95% confidence interval (CI): 0.770–0.774) in the training group and was 0.769 (95% CI: 0.765–0.773) in the validation group. These results ultimately displayed adequate discrimination ability in the prediction of NSCLC patients’ absolute risk. The calibration curves, which were validated using the bootstrap resampling method, indicated that the predictive power of the nomogram was in accordance with the actual observed values in both groups (Figure 3). The correlation between the predictive power of OS and the different subdivision levels of VPI shown in Figure 4, which was depicted using Kaplan–Meier curves, could display the survival differences in both the training and the validation groups.
The incidence rate of VPI accounts for approximately 11.5% of NSCLC patients and varies between different histological types . According to the 7th edition of the AJCC/UICC TNM staging system, stage T1a (≤2 cm) and stage T1b (>2 cm and ≤3 cm) can be classified based on the tumor size, whereas VPI confirmed by the pathology finding in NSCLC patients with stage T1 (≤3 cm) can be upgraded to stage T2a. Nonetheless, the detailed subdivision levels of VPI are not incorporated into the T stage in the TNM staging system (8th edition). Some [15–17] but not all [18, 19] studies showed that NSCLC patients with VPI had a worse prognosis than those without VPI. Moreover, due to the presence of an independent risk factor for visceral pleural invasion, the relationship between tumor staging and tumor sizes remained controversial. The application of pleural biopsy or medical thoracoscopy is the optional method to estimate the extent of VPI. The clinician often considers various limiting factors such as the increasing risk of malignancy, expertise, surgical complication, and so on. Thus, the extent of VPI can be predicted by imaging examinations, such as B-ultrasound, computed tomography, and other methods. However, the single prediction method and the increase of medical cost may influence diagnostic accuracy and wide clinical practice. Combination with other simple and effective methods has meaningful clinical application value. Therefore, we performed this study to establish a simple predictive tool that can assist clinicians to make the preliminary screening.
Nomograms are prognostic tools that make complex statistical models simpler with terse diagrams, which supply more exact and understandable prognosis predicting results and are widely applied in clinical practice [20, 21]. Predictive models based on large sample data from the SEER database might be less prone to the bias that is selected by the null hypothesis. Meanwhile, due to the lack of details of population-based data, the analyses of the nomogram model derived from the SEER database might be more accurate and more likely to conquer bias through institutional practice . Many clinical research works [23–26] established nomogram prognostic models to provide survival counseling and follow-up strategy-making. These results demonstrated the efficiency of the nomogram predictive tool in clinical practices. Considering the friendly clinician-oriented interface and accurate predictions, therefore, we performed nomograms, which were derived from the SEER database, to predict the correlation with the subdivision level of VPI and the OS of NSCLC patients. We selected the independent prognostic factors using univariate and multivariate Cox proportional hazards regressions to construct the nomogram model. The OS, defined as the time from diagnosis to death of any cause, was assessed by the Kaplan–Meier method and tested by the log-rank test. Consistent with many previous studies [15, 18, 27], the negative correlation between the subdivision level of VPI and the OS of NSCLC patients was revealed. Meanwhile, we found that the subdivision level of VPI could add additional predicting information for OS beyond the other clinical parameters, including age, gender, race, histopathology, and so on, indicating that subdivision of VPI is an independent and strong predictor. In this nomogram prognostic model, a C-index of greater than 0.7 in both the training and the validation groups displayed adequate discrimination ability, and the calibration plots showed good consistency between the predicted and the actual observed values.
Many clinical studies have shown that NSCLC patients with VPI have poorer survival as compared with those without. The possible factors for poor prognosis are associated with higher involvement in mediastinal lymph nodes [28–30]. On the other hand, lung cancer cells under the pleural are more likely to invade the pleural layer rapidly through the flow of pleural effusions in the pleural cavity. Once diaphragmatic lymph nodes have been involved, malignant cells will further be drained to mediastinal lymphatic vessels. In this way, cervical venous circulation is easier to be invaded in the spreading of malignant cells and facilitates metastasis. Malignant tumor cells have increasingly aggressive and progressive biological characteristics with the increasing level of VPI and contribute to adverse outcomes for these NSCLC patients. Some studies have revealed the link between marital status and survival in cancer patients. Meanwhile, several potential mechanisms may explain the correlation. First, patients who are married have less distress and depression than unmarried patients after a diagnosis of cancer, as a partner can share the emotional burden and provide the appropriate social support. Chronic stress, loneliness, and depression can downregulate the immune responses; stimulate tumor angiogenesis; and increase tumor burden and invasiveness [31–34]. Second, patients with emotional and financial support from their spouses or children had better compliance from doctors .
There are several limitations in this population-based study. All of the data from the SEER database, which has a retrospective nature, contain bias that should be taken into consideration. First, the different medical agencies and professionals, including pathologists, surgeons, and so on, influence the detection rates and the quality of pleural invasion. Moreover, the SEER database fails to provide other information regarding NSCLC patients with VPI including the method of detection, complications, pulmonary function, and treatment method, which could generate underlying bias as well. Thus, it is useful to improve the accuracy of predictive models by incorporating novel predictors and introducing competing risk models. Moreover, the inclusion of the degree of VPI of early-stage NSCLC patients might also be a good candidate to control the confounding factors. Second, it is a common issue that improved accuracy of the predictive model is usually accompanied by a compromise between the increasing complexity of predictive factors and the decreasing understandability of the model during the modeling process of the nomogram. Considering the aforementioned, variables of clinical importance and high repeatable practicability would be preferred. Moreover, the nomogram itself needs to be confirmed using calibration plots and the C-index due to its uncertainty. Nonetheless, the nomogram is a powerful supplement for clinician judgment and clinical decision-making. Third, occult pleural metastases, which cannot be assessed by routine pathological examination, can only be detected during thoracotomy. Considering this study’s retrospective nature, the selection bias could not be avoided. In this study, whether patients diagnosed as PL0 actually have occult pleural metastases is still unclear. Besides this, patients who displayed no signs of pleural invasion based on clinical and/or radiographic judgment cannot exclude the possibility of occult micrometastases. Risk factors of these patients were relatively higher than those diagnosed with VPI. Fourth, based on the SEER database, we randomly divided the data into the training and the validation groups at the ratio of 7:3. This method of nomogram construction and validation is common, whereas further external verification was not available. Hence, we will focus on the data from multiple medical centers in further research to perform the validation of the external cohort.
We developed and validated a population-based nomogram model to predict survival differences among the different subdivision levels of VPI in NSCLC patients. This study provides a novel perspective that helps clinicians determine survival prognosis and establish personalized treatment strategies for NSCLC patients with varying degrees of VPI, which is an effective supplement to traditional TNM staging.
The data used to support the findings of this study are available from the corresponding author upon request.
The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SEER database is the leading cancer statistics database in the United States, and it is globally open and shared. The authors obtained the data by applying to the authorities.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Conceptualization was performed by Fan Wang. Methodology was developed by Fan Wang and Pei Li. Software was provided by Fan Wang. Validation was performed by Fan Wang and Pei Li. Formal Analysis was performed by Fan Wang. Investigation was done by Fan Wang and Pei Li. Original draft was written by Fan Wang. Reviewing and editing were performed by Fengsen Li. Supervision was done by Fengsen Li.
This research received a specific grant from the Natural Science Foundation of Xinjiang Uygur Autonomous Region (no. 2019D01A06) and Special Project of Xinjiang Public Health Key Technology Research and Development and Epidemic Prevention System Construction (no. 2020A03004).
- F. R. Hirsch, G. V. Scagliotti, J. L. Mulshine et al., “Lung cancer: current therapies and new targeted treatments,” The Lancet, vol. 389, no. 10066, pp. 299–311, 2017.
- F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
- R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017.
- C. F. Mountain, “Revisions in the international system for staging lung cancer,” Chest, vol. 111, no. 6, pp. 1710–1717, 1997.
- W. D. Travis, E. Brambilla, R. Rami-Porta et al., “Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer,” Journal of Thoracic Oncology, vol. 3, no. 12, pp. 1384–1390, 2008.
- P. Goldstraw, K. Chansky, J. Crowley et al., “The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer,” Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, vol. 11, no. 1, pp. 39–51, 2016.
- P. Goldstraw, J. Crowley, K. Chansky et al., “The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours,” Journal of Thoracic Oncology, vol. 2, no. 8, pp. 706–714, 2007.
- D. R. Jones, T. M. Daniel, C. E. Denlinger, B. K. Rundall, M. E. Smolkin, and M. R. Wick, “Stage IB nonsmall cell lung cancers: are they all the same?” The Annals of Thoracic Surgery, vol. 81, no. 6, pp. 1958–1962, 2006.
- S.-I. Takeda, S. Fukai, H. Komatsu, E. Nemoto, K. Nakamura, and M. Murakami, “Impact of large tumor size on survival after resection of pathologically node negative (pN0) non-small cell lung cancer,” The Annals of Thoracic Surgery, vol. 79, no. 4, pp. 1142–1146, 2005.
- B. H. Bochner, B. H. Bochner, M. W. Kattan, and K. C. Vora, “Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 24, no. 24, pp. 3967–3972, 2006.
- P. I. Karakiewicz, A. Briganti, F. K.-H. Chun et al., “Multi-institutional validation of a new renal cancer-specific survival nomogram,” Journal of Clinical Oncology, vol. 25, no. 11, pp. 1316–1322, 2007.
- K. A. Cronin, L. A. Ries, and B. K. Edwards, “The surveillance, Epidemiology, and End results (SEER) program of the national cancer Institute,” Cancer, vol. 120, no. 23, pp. 3755–3757, 2014.
- G. Heller and Q. Mo, “Estimating the concordance probability in a survival analysis with a discrete number of risk groups,” Lifetime Data Analysis, vol. 22, no. 2, pp. 263–279, 2016.
- Y. Taniguchi, H. Nakamura, K. Miwa et al., “Prognostic significance of pleural lavage cytology after thoracotomy and before closure of the chest in lung cancer,” Interactive CardioVascular and Thoracic Surgery, vol. 9, no. 1, pp. 102–106, 2009.
- Y. Kudo, H. Saji, Y. Shimada et al., “Impact of visceral pleural invasion on the survival of patients with non-small cell lung cancer,” Lung Cancer, vol. 78, no. 2, pp. 153–160, 2012.
- J. J. Fibla, S. D. Cassivi, A. Brunelli et al., “Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set,” Lung Cancer, vol. 78, no. 3, pp. 259–262, 2012.
- N. Yanagawa, S. Shiono, M. Abiko, S.-y. Ogata, T. Sato, and G. Tamura, “Prognostic impact and initial recurrence site of lymphovascular and visceral pleural invasion in surgically resected stage I non-small-cell lung carcinoma,” European Journal of Cardio-Thoracic Surgery, vol. 44, no. 3, pp. e200–e206, 2013.
- E. David, P. F. Thall, N. Kalhor et al., “Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size,” The Annals of Thoracic Surgery, vol. 95, no. 6, pp. 1872–1877, 2013.
- A. Kawase, J. Yoshida, E. Miyaoka et al., “Visceral pleural invasion classification in non-small-cell lung cancer in the 7th edition of the tumor, node, metastasis classification for lung cancer: validation analysis based on a large-scale nationwide database,” Journal of Thoracic Oncology, vol. 8, no. 5, pp. 606–611, 2013.
- A. Iasonos, D. Schrag, G. V. Raj, and K. S. Panageas, “How to build and interpret a nomogram for cancer prognosis,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1364–1370, 2008.
- S. F. Shariat, P. I. Karakiewicz, N. Suardi, and M. W. Kattan, “Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature,” Clinical Cancer Research, vol. 14, no. 14, pp. 4400–4407, 2008.
- V. P. Balachandran, M. Gonen, J. J. Smith, and R. P. DeMatteo, “Nomograms in oncology: more than meets the eye,” The Lancet Oncology, vol. 16, no. 4, pp. e173–e180, 2015.
- Y. Zhang, D. Zheng, J. Xie et al., “Development and validation of web-based nomograms to precisely predict conditional risk of site-specific recurrence for patients with completely resected non-small cell lung cancer,” Chest, vol. 154, no. 3, pp. 501–511, 2018.
- Q. Mao, W. Xia, G. Dong et al., “A nomogram to predict the survival of stage IIIA-N2 non-small cell lung cancer after surgery,” The Journal of Thoracic and Cardiovascular Surgery, vol. 155, no. 4, pp. 1784–1792, 2018.
- Y. Wang, R. Wang, D. Zheng et al., “Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma ≤3 cm with wedge resection,” Journal of Cancer Research and Clinical Oncology, vol. 143, no. 6, pp. 1043–1051, 2017.
- J. Qian, J. Xu, S. Wang et al., “Adjuvant chemotherapy candidates in stage I lung adenocarcinomas following complete lobectomy,” Annals of Surgical Oncology, vol. 26, no. 8, pp. 2392–2400, 2019.
- M. Riquet, A. Arame, and P. Mordant, “Visceral pleural invasion: a prognostic factor beginning with small size and increasing with the progression of lung cancer,” The Annals of Thoracic Surgery, vol. 97, no. 1, p. 383, 2014.
- K. Shimizu, J. Yoshida, K. Nagai et al., “Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer,” The Journal of Thoracic and Cardiovascular Surgery, vol. 130, no. 1, pp. 160–165, 2005.
- D. Manac’h, M. Riquet, J. Medioni, F. Le Pimpec-Barthes, A. Dujon, and C. Danel, “Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor,” The Annals of Thoracic Surgery, vol. 71, no. 4, pp. 1088–1093, 2001.
- J. Kang, K. D. Kim, and K. Y. Chung, “Prognostic value of visceral pleura invasion in non-small cell lung cancer,” European Journal of Cardio-Thoracic Surgery, vol. 23, no. 6, pp. 865–869, 2003.
- N. C. Kaiser, N. Hartoonian, and J. E. Owen, “Toward a cancer-specific model of psychological distress: population data from the 2003-2005 National Health Interview Surveys,” Journal of Cancer Survivorship, vol. 4, no. 4, pp. 291–302, 2010.
- J. L. Pike and M. R. Irwin, “Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder,” Brain, Behavior, and Immunity, vol. 20, no. 2, pp. 169–174, 2006.
- L. M. Jaremka, J. Peng, R. Bornstein et al., “Cognitive problems among breast cancer survivors: loneliness enhances risk,” Psycho-Oncology, vol. 23, no. 12, pp. 1356–1364, 2014.
- D. W. Kissane, “Unrecognised and untreated depression in cancer care,” The Lancet Psychiatry, vol. 1, no. 5, pp. 320-321, 2014.
- M. R. DiMatteo, H. S. Lepper, and T. W. Croghan, “Depression is a risk factor for noncompliance with medical treatment,” Archives of Internal Medicine, vol. 160, no. 14, pp. 2101–2107, 2000.
Copyright © 2021 Fan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.